MRI-Guided Therapeutic Procedures in Recurrent Prostate Cancer

  • David A. Woodrum
  • Akira Kawashima
  • Krzysztof R. Gorny
  • Lance A. Mynderse
Part of the Medical Radiology book series (MEDRAD)


The American Cancer Society estimated that 217,730 new cases of prostate cancer would be diagnosed in the USA in 2010 (Jemal et al. in CA Cancer J Clin 60(5):277−300, 2010). Many men with prostate cancer are often treated with aggressive therapy, including radiotherapy, surgery, or androgen deprivation. No matter how expertly done, these therapies have significant risk and affect the patient’s health-related quality of life, with impact on sexual, urinary, and bowel function (Potosky et al. in J Natl Cancer Inst 96(18):1358−1367, 2004). Active screening programs for prostate cancer have identified increasing numbers of low-risk prostate cancer that have encouraged regimens of active surveillance to delay treatment until cancer progression (Jemal et al. in CA Cancer J Clin 56(2):106−130, 2006). Although active debate continues on the suitability of focal or regional therapy for these low-risk prostate cancer patients, many unresolved issues remain which complicate this management approach. Among them are prostate cancer multifocality, limitations of current biopsy strategies, suboptimal staging by accepted imaging modalities, and less than robust prediction models for indolent prostate cancers. In spite of these restrictions, focal therapy continues to confront the current paradigm of therapy for low-risk disease (Onik et al. in Urology 70(6 Suppl):16−21, 2007). When accurate staging and characterization of the risk posed by a particular prostate cancer is achieved, focal therapy will become a viable option for the management of prostate cancer.


Radical Prostatectomy Ablation Zone Local Recurrent Tumor Dynamic Contrast Enhancement Prostatic Fossa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Biochemical recurrence


Magnetic resonance imaging


Biochemical disease-free survival


High-intensity focused ultrasound


Prostate-specific antigen


Laser interstitial therapy


Laser-diffusing fiber


Dynamic contrast enhancement


  1. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR (2008) Cancer of the prostate strategic urological research endeavor. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112(2):307–314PubMedCrossRefGoogle Scholar
  2. Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H (1999) Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 161(3):857–862; discussion 862–853PubMedCrossRefGoogle Scholar
  3. Baissalov R, Sandison GA, Donnelly BJ, Saliken JC, McKinnon JG, Muldrew K, Rewcastle JC (2000) A semi-empirical treatment planning model for optimization of multiprobe cryosurgery. Phys Med Biol 45(5):1085–1098PubMedCrossRefGoogle Scholar
  4. Bianco FJ Jr, Scardino PT, Stephenson AJ, DiBlasio CJ, Fearn PA, Eastham JA (2005) Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 62(2):448–453PubMedCrossRefGoogle Scholar
  5. Boris RS, Bhandari A, Krane LS, Eun D, Kaul S, Peabody JO (2009) Salvage robotic-assisted radical prostatectomy: initial results and early report of outcomes. BJU Int 103(7):952–956PubMedCrossRefGoogle Scholar
  6. Brandeis J, Pashos CL, Henning JM, Litwin MS (2000) A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 89(8):1792–1799PubMedCrossRefGoogle Scholar
  7. Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, Gualdi GF (2008) Gualdi GF. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 190(5):1187–1192PubMedCrossRefGoogle Scholar
  8. Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB (2001) Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 165(6 Pt 1):1937–1941; discussion 1941–1932PubMedGoogle Scholar
  9. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, Ortega C, Gabriele P, Regge D (2009) Endorectal magnetic resonance imaging at 1.5 tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19(3):761–769PubMedCrossRefGoogle Scholar
  10. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR (1996) Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47(2):225–231PubMedCrossRefGoogle Scholar
  11. Elhawary H, Zivanovic A, Rea M, Davies B, Besant C, McRobbie D, de Souza N, Young I, Lamperth M (2006) The feasibility of MR-image guided prostate biopsy using piezoceramic motors inside or near to the magnet isocentre. Med Image Comput Comput Assist Interv 9(Pt 1):519–526PubMedGoogle Scholar
  12. Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouviere O, Curiel L, Janier M, Vallancien G (2004) Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63(4):625–629PubMedCrossRefGoogle Scholar
  13. Gorny K, King D, Felmlee J, Rossman P, Woodrum D, Mynderse L (2011) In vitro investigations of the urethral warmer on isotherms during interstitial cryoablations for prostate cancer. Med Phys 38:3483Google Scholar
  14. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, Larson TR, Wilkes MM, Navickis RJ (1999) Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53(1):2–10PubMedCrossRefGoogle Scholar
  15. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics. CA Cancer J Clin 56(2):106–130PubMedCrossRefGoogle Scholar
  16. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60(5):277–300PubMedCrossRefGoogle Scholar
  17. Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ (2010) Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int 105(2):191–201PubMedCrossRefGoogle Scholar
  18. Koutrouvelis P, Hendricks F, Lailas N, Gil-Montero G, Sehn J, Khawand N, Bondy H, Katz S (2003) Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat 2(4):339–344PubMedGoogle Scholar
  19. Kramer S, Gorich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N, Brambs HJ, Sokiranski R (1997) Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 70(838):995–999PubMedGoogle Scholar
  20. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL (2003) Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57(4):915–928PubMedCrossRefGoogle Scholar
  21. Lagerburg V, Moerland MA, van Vulpen M, Lagendijk JJW (2006) A new robotic needle insertion method to minimise attendant prostate motion. Radiother Oncol 80(1):73–77PubMedCrossRefGoogle Scholar
  22. Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219(2):432–439PubMedGoogle Scholar
  23. McNichols RJ, Gowda A, Kangasniemi M, Bankson JA, Price RE, Hazle JD (2004) MR thermometry-based feedback control of laser interstitial thermal therapy at 980 nm. Lasers Surg Med 34(1):48–55PubMedCrossRefGoogle Scholar
  24. McNichols RJ, Gowda A, Gelnett MD, Stafford RJ (2005) Percutaneous MRI-guided laser thermal therapy in canine prostate. SPIE, San Jose, pp 214–225Google Scholar
  25. Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163(6):1632–1642PubMedCrossRefGoogle Scholar
  26. Murat F-J, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon J-Y, Gelet A (2009) Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55(3):640–647PubMedCrossRefGoogle Scholar
  27. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J (2007) “Male lumpectomy”: focal therapy for prostate cancer using cryoablation. Urology 70(6 Suppl):16–21PubMedCrossRefGoogle Scholar
  28. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43(5):649–659PubMedCrossRefGoogle Scholar
  29. Patel A, Dorey F, Franklin J, de Kernion JB (1997) Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158(4):1441–1445PubMedCrossRefGoogle Scholar
  30. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS (2008) Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol 180(2):559–563; discussion 563–554PubMedCrossRefGoogle Scholar
  31. Porter CA 4th, Woodrum DA, Callstrom MR, Schmit GD, Misra S, Charboneau JW, Atwell TD (2010) MRI after technically successful renal cryoablation: early contrast enhancement as a common finding. AJR Am J Roentgenol 194(3):790–793PubMedCrossRefGoogle Scholar
  32. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96(18):1358–1367PubMedCrossRefGoogle Scholar
  33. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597PubMedCrossRefGoogle Scholar
  34. Reske SN, Blumstein NM, Glatting G (2008) [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35(1):9–17PubMedCrossRefGoogle Scholar
  35. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H (2001) PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76(6):576–581PubMedGoogle Scholar
  36. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, Passariello R, Di Silverio F, Gentile V (2008) Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54(3):589–600PubMedCrossRefGoogle Scholar
  37. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231(2):379–385PubMedCrossRefGoogle Scholar
  38. Siddiqui SA, Mynderse LA, Zincke H, Hoffmann NE, Lobo JR, Wilson TM, Kawashima A, Davis BJ, Blute ML (2007) Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience. Urology 70(1):80–85PubMedCrossRefGoogle Scholar
  39. Stephenson AJ, Slawin KM (2004) The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Nat Clin Pract Urol 1(2):90–96PubMedCrossRefGoogle Scholar
  40. Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Usui Y, Nagata Y (2011) High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. BJU Int 107(3):378–382PubMedCrossRefGoogle Scholar
  41. van den Bosch MR, Moman MR, van Vulpen M, Battermann JJ, Duiveman E, van Schelven LJ, de Leeuw H, Lagendijk JJW, Moerland MA (2010) MRI-guided robotic system for transperineal prostate interventions: proof of principle. Phys Med Biol 55(5):N133–N140PubMedCrossRefGoogle Scholar
  42. Woodrum DA, Gorny KR, Mynderse LA, Amrami KK, Felmlee JP, Bjarnason H, Garcia-Medina OI, McNichols RJ, Atwell TD, Callstrom MR (2010) Feasibility of 3.0T magnetic resonance imaging-guided laser ablation of a cadaveric prostate. Urology 75(6):1514.e1511–1514.e1516CrossRefGoogle Scholar
  43. Young JL, Kolla SB, Pick DL, Sountoulides P, Kaufmann OG, Ortiz-Vanderdys CG, Huynh VB, Kaplan AG, Andrade LA, Osann KE, Louie MK, McDougall EM, Clayman RV (2010) In vitro, ex vivo and in vivo isotherms for renal cryotherapy. J Urol 183(2):752–758PubMedCrossRefGoogle Scholar
  44. Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, Allen C, Emberton M (2008) The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int 102(7):786–792PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • David A. Woodrum
    • 1
  • Akira Kawashima
    • 1
  • Krzysztof R. Gorny
    • 1
  • Lance A. Mynderse
    • 2
  1. 1.Department of RadiologyMayo ClinicRochesterUSA
  2. 2.Department of UrologyMayo ClinicRochesterUSA

Personalised recommendations